Skip to main content

Advertisement

Table 2 Squalestatin reduces co-localisation between MoPrP105-132 and cPLA2/COX-1. The percentage of MoPrP105-132 that co-localised with the signalling enzymes cPLA2 or COX-1 in untreated neuroblastoma cells and cells treated for 24 hours with either 1 μM squalestatin or 2 Hexa-PAF, 5 minutes after the addition of peptide. Values shown are mean ± SD, calculated after counting a minimum of 3 cells.

From: Squalestatin alters the intracellular trafficking of a neurotoxic prion peptide

Co-localisation with MoPrP105-132 Drug Treatments
  Untreated Squalestatin Hexa-PAF
cPLA2 38% ± 7 13% ± 4 22% ± 6
COX-1 70% ± 5 5% ± 5 13% ± 3